Gold prices near 3-week lows as stronger dollar, trade progress weigh
Investing.com -- Pfizer (NYSE:PFE), a prominent drugmaker, has offloaded its entire stake in Haleon to institutional investors and the consumer healthcare firm.
The deal, which was completed at 385 pence per share, is estimated to be worth around 2.5 billion pounds ($3.24 billion), according to a bookrunner involved in the transaction.
As part of the agreement, Haleon, known for producing Sensodyne, has consented to repurchase 44 million of its shares from Pfizer.
The total transaction accounts for 7.3% of Haleon’s issued share capital.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.